Literature DB >> 196546

Antiviral activity of 3-deazaguanine, 3-deazaguanosine, and 3-deazaguanylic acid.

L B Allen, J H Huffman, P Dan Cook, R B Meyer, R K Robins, R W Sidwell.   

Abstract

3-Deazaguanine (ICN 4221), 3-deazaguanosine (ICN 4793), and 3-deazaguanylic acid (ICN 5412) represent a new class of synthetic guanine analogs having antiviral activity. In vitro, nine ribonucleic acid and seven deoxyribonucleic acid viruses were inhibited, including influenza, parainfluenza, rhino-, vesicular stomatitis, adeno-, herpes-, cytomegalo-, vaccinia, pseudorabies, and myxoma viruses. They were effective orally against influenza types A and B and parainfluenza type 1 (Sendai) virus infections in mice, with a therapeutic index of 16 against the latter two viruses. The course of herpes encephalitis was altered only when the drugs were applied directly into the brain. In addition, these drugs were effective inhibitors of Friend leukemia virus-induced splenomegaly in mice; treatment also produced extensions of life in these animals.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 196546      PMCID: PMC352163          DOI: 10.1128/AAC.12.1.114

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Inhibition of purine nucleotide biosynthesis by 3-deazaguanine, its nucleoside and 5'-nucleotide.

Authors:  D G Streeter; H H Koyama
Journal:  Biochem Pharmacol       Date:  1976-11-01       Impact factor: 5.858

2.  Synthesis of 3-deazaguanine, 3-deazaguanosine, and 3-deazaguanylic acid by a novel ring closure of imidazole precursors.

Authors:  P D Cook; R J Rousseau; A M Mian; P Dea; R B Meyer; R K Robins
Journal:  J Am Chem Soc       Date:  1976-03-17       Impact factor: 15.419

3.  Design, synthesis, and broad spectrum antiviral activity of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides.

Authors:  J T Witkowski; R K Robins; R W Sidwell; L N Simon
Journal:  J Med Chem       Date:  1972-11       Impact factor: 7.446

4.  Use of disposable micro tissue culture plates for antiviral and interferon induction studies.

Authors:  R W Sidwell; J H Huffman
Journal:  Appl Microbiol       Date:  1971-11

5.  A new class of synthetic nucleoside analogues with broad-spectrum antiviral properties.

Authors:  P Prusiner; M Sundaralingam
Journal:  Nat New Biol       Date:  1973-07-25

6.  Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide.

Authors:  R W Sidwell; J H Huffman; G P Khare; L B Allen; J T Witkowski; R K Robins
Journal:  Science       Date:  1972-08-25       Impact factor: 47.728

7.  Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent.

Authors:  D G Streeter; J T Witkowski; G P Khare; R W Sidwell; R J Bauer; R K Robins; L N Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1973-04       Impact factor: 11.205

8.  In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses.

Authors:  J H Huffman; R W Sidwell; G P Khare; J T Witkowski; L B Allen; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

9.  Target-organ treatment of neurotropic virus diseases: efficacy as a chemotherapy tool and comparison of activity of adenine arabinoside, cytosine arabinoside, idoxuridine, and trifluorothymidine.

Authors:  L B Allen; R W Sidwell
Journal:  Antimicrob Agents Chemother       Date:  1972-09       Impact factor: 5.191

  9 in total
  10 in total

1.  Studies on the mechanism of 3-deazaguanine cytotoxicity in L1210-sensitive and -resistant cell lines.

Authors:  G Singh; M K Luna; B Ardalan
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  Base-functionalized carbocyclic nucleosides: design, synthesis, and mechanism of antiviral activity.

Authors:  Vasu Nair; Fan Zhang; Xiaohui Ma; Eric Bonsu
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2009-05       Impact factor: 1.381

3.  Antirhinovirus activity of purine nucleoside analogs.

Authors:  E De Clercq; R Bernaerts; D E Bergstrom; M J Robins; J A Montgomery; A Holy
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191

4.  Susceptibilities of enterovirus D68, enterovirus 71, and rhinovirus 87 strains to various antiviral compounds.

Authors:  Donald F Smee; W Joseph Evans; K C Nicolaou; E Bart Tarbet; Craig W Day
Journal:  Antiviral Res       Date:  2016-04-07       Impact factor: 5.970

5.  Inhibitory effects of antiviral compounds on respiratory syncytial virus replication in vitro.

Authors:  F Kawana; S Shigeta; M Hosoya; H Suzuki; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

6.  Studies on the mechanism of cytotoxicity of 3-deazaguanosine in human cancer cells.

Authors:  T Page; S J Jacobsen; R M Smejkal; J Scheele; W L Nyhan; J H Mangum; R K Robins
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  Comparative activities of several nucleoside analogs against influenza A, B, and C viruses in vitro.

Authors:  S Shigeta; K Konno; T Yokota; K Nakamura; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

8.  Selective inhibitory effect of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 2'-nor-cyclic GMP on adenovirus replication in vitro.

Authors:  M Baba; S Mori; S Shigeta; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

9.  Broad-spectrum synergistic antiviral activity of selenazofurin and ribavirin.

Authors:  J J Kirsi; P A McKernan; N J Burns; J A North; B K Murray; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

10.  Evaluation of cell viability dyes in antiviral assays with RNA viruses that exhibit different cytopathogenic properties.

Authors:  Donald F Smee; Brett L Hurst; W Joseph Evans; Nathan Clyde; Sean Wright; Christopher Peterson; Kie-Hoon Jung; Craig W Day
Journal:  J Virol Methods       Date:  2017-03-27       Impact factor: 2.623

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.